Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2

Allergic individuals at risk for hypersensitivity reactions to measles vaccine marketed for a long time are well established. On the other hand, risk factors for hypersensitivity reactions to the new mRNA COVID‐19 vaccines currently include a history of allergy, allergy to excipient of the vaccine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Caffarelli, Carlo, Liotti, Lucia, Bianchi, Annamaria, Bottau, Paolo, Caimmi, Silvia, Crisafulli, Giuseppe, Franceschini, Fabrizio, Paglialunga, Claudia, Saretta, Francesca, Mori, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303687/
https://www.ncbi.nlm.nih.gov/pubmed/35080320
http://dx.doi.org/10.1111/pai.13631
Descripción
Sumario:Allergic individuals at risk for hypersensitivity reactions to measles vaccine marketed for a long time are well established. On the other hand, risk factors for hypersensitivity reactions to the new mRNA COVID‐19 vaccines currently include a history of allergy, allergy to excipient of the vaccine, or hypersensitivity reactions to the first dose of COVID‐19 vaccine. In the last two cases, the recipient should be assessed by an allergist before vaccination to share a decision on the choice of vaccination. Studies on skin testing accuracy and desensitization protocols to the COVID‐19 vaccines and the efficacy of potential alternatives in patients with confirmed hypersensitivity reactions to the first COVID‐19 vaccine are necessary to improve the safety of COVID‐19 vaccines.

Ejemplares similares